PL3428194T3 - Ulepszona cząsteczka polipeptydu o podwójnej specyficzności - Google Patents
Ulepszona cząsteczka polipeptydu o podwójnej specyficznościInfo
- Publication number
- PL3428194T3 PL3428194T3 PL18183508T PL18183508T PL3428194T3 PL 3428194 T3 PL3428194 T3 PL 3428194T3 PL 18183508 T PL18183508 T PL 18183508T PL 18183508 T PL18183508 T PL 18183508T PL 3428194 T3 PL3428194 T3 PL 3428194T3
- Authority
- PL
- Poland
- Prior art keywords
- specific polypeptide
- improved double
- double specific
- polypeptide particle
- particle
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/112—Retroviridae (F), e.g. leukemia viruses
- C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- AIDS & HIV (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762532713P | 2017-07-14 | 2017-07-14 | |
| DE102017115966.5A DE102017115966A1 (de) | 2017-07-14 | 2017-07-14 | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
| DE102017119866 | 2017-08-30 | ||
| US201862658318P | 2018-04-16 | 2018-04-16 | |
| DE102018108995 | 2018-04-16 | ||
| EP18183508.3A EP3428194B1 (en) | 2017-07-14 | 2018-07-13 | Improved dual specificity polypeptide molecule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3428194T3 true PL3428194T3 (pl) | 2022-01-17 |
Family
ID=62951983
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18740829T PL3652215T3 (pl) | 2017-07-14 | 2018-07-13 | Ulepszona cząsteczka polipeptydu o podwójnej specyficzności |
| PL18183508T PL3428194T3 (pl) | 2017-07-14 | 2018-07-13 | Ulepszona cząsteczka polipeptydu o podwójnej specyficzności |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18740829T PL3652215T3 (pl) | 2017-07-14 | 2018-07-13 | Ulepszona cząsteczka polipeptydu o podwójnej specyficzności |
Country Status (28)
| Country | Link |
|---|---|
| US (8) | US11905328B2 (pl) |
| EP (3) | EP3985029A1 (pl) |
| JP (4) | JP2020530762A (pl) |
| KR (2) | KR20200026995A (pl) |
| CN (2) | CN110914308A (pl) |
| AU (2) | AU2018298884A1 (pl) |
| BR (2) | BR112020000762A2 (pl) |
| CA (2) | CA3069842A1 (pl) |
| CO (2) | CO2020001029A2 (pl) |
| CR (2) | CR20200014A (pl) |
| CY (2) | CY1124091T1 (pl) |
| DK (2) | DK3652215T3 (pl) |
| ES (2) | ES2898210T3 (pl) |
| HR (1) | HRP20211744T1 (pl) |
| HU (2) | HUE054568T2 (pl) |
| LT (2) | LT3428194T (pl) |
| MA (1) | MA46299B1 (pl) |
| MD (2) | MD3652215T2 (pl) |
| MX (1) | MX2020011744A (pl) |
| PE (2) | PE20200614A1 (pl) |
| PL (2) | PL3652215T3 (pl) |
| PT (2) | PT3428194T (pl) |
| RS (2) | RS61817B1 (pl) |
| SG (2) | SG11202000025SA (pl) |
| SI (2) | SI3652215T1 (pl) |
| TW (2) | TWI762677B (pl) |
| WO (2) | WO2019012141A1 (pl) |
| ZA (1) | ZA202000842B (pl) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| PT3428194T (pt) | 2017-07-14 | 2021-11-18 | Immatics Biotechnologies Gmbh | Molécula de polipéptido com especificidade dupla melhorada |
| US20210363216A1 (en) | 2018-05-14 | 2021-11-25 | Immunocore Limited | Bifunctional binding polypeptides |
| GB201904328D0 (en) | 2019-03-28 | 2019-05-15 | Immunocore Ltd | Specific binding molecules |
| MA56036A (fr) | 2019-05-27 | 2022-04-06 | Immatics Us Inc | Vecteurs viraux et leur utilisation dans une thérapie cellulaire adoptive |
| US20210032370A1 (en) * | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| CN112409474B (zh) * | 2019-08-23 | 2023-02-28 | 香雪生命科学技术（广东）有限公司 | 一种识别ssx2抗原的高亲和力tcr |
| GB201915282D0 (en) | 2019-10-22 | 2019-12-04 | Immunocore Ltd | Specific binding molecules |
| CN114786720B (zh) * | 2019-12-05 | 2025-08-22 | 艾贝乐医药科技有限公司 | TriAx抗体的组合物及其制备和使用方法 |
| AU2021225817A1 (en) | 2020-02-24 | 2022-10-20 | Immatics US, Inc. | Methods for expanding T cells for the treatment of cancer and related malignancies |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| GB202006629D0 (en) | 2020-05-05 | 2020-06-17 | Immunocore Ltd | Specific binding molecules |
| GB202010329D0 (en) | 2020-07-06 | 2020-08-19 | Immunocore Ltd | Specific binding molecules |
| US20220056411A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| PE20250846A1 (es) | 2020-12-31 | 2025-03-21 | Immatics Us Inc | Polipeptidos cd8, composiciones y metodos de uso de estos |
| WO2022184805A1 (en) | 2021-03-03 | 2022-09-09 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein |
| US12435444B2 (en) | 2021-03-09 | 2025-10-07 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same |
| BR112023022765A2 (pt) | 2021-05-05 | 2024-01-02 | Immatics Biotechnologies Gmbh | Proteínas de ligação ao antígeno que ligam especificamente o prame |
| US20230024554A1 (en) | 2021-06-28 | 2023-01-26 | Immatics Biotechnologies Gmbh | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| EP4113120A1 (en) | 2021-06-28 | 2023-01-04 | Immatics Biotechnologies GmbH | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| JP2024529467A (ja) | 2021-07-27 | 2024-08-06 | イマティクス バイオテクノロジーズ ゲーエムベーハー | Ｃｔ４５に特異的に結合する抗原結合タンパク質 |
| CN115724988B (zh) * | 2021-08-26 | 2023-11-17 | 瑅安生物医药（杭州）有限公司 | 一种接近天然分子的多肽融合分子 |
| WO2023044488A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| US20230190806A1 (en) | 2021-10-06 | 2023-06-22 | Immatics Biotechnologies Gmbh | Methods of treating metastatic lesions and compositions thereof |
| US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| WO2023081461A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
| KR20240116828A (ko) * | 2021-12-14 | 2024-07-30 | 씨디알-라이프 아게 | 이중 mhc-표적화 t 세포 관여자 |
| AU2023222190A1 (en) | 2022-02-20 | 2024-08-29 | Immunocore Limited | Hiv-specific binding molecules and tcr |
| EP4514834A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| EP4514821A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| IL316515A (en) | 2022-04-28 | 2024-12-01 | Immatics Us Inc | Membrane-bound IL15 CD8 proteins, cells, compositions and methods for their use |
| US20250354995A1 (en) * | 2022-04-29 | 2025-11-20 | Immatics Biotechnologies Gmbh | Mammalian display platform for multispecific antigen binding proteins |
| US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
| WO2024033332A1 (en) | 2022-08-08 | 2024-02-15 | Immatics Biotechnologies Gmbh | Guided positional scanning method |
| CN120202015A (zh) | 2022-09-14 | 2025-06-24 | Cdr-生物科技股份有限公司 | Mage-a4肽双重t细胞衔接子 |
| EP4634216A1 (en) | 2022-12-16 | 2025-10-22 | Repertoire Immune Medicines, Inc. | T cell receptors binding hpv-16 epitopes |
| EP4646268A1 (en) | 2023-01-06 | 2025-11-12 | Immunocore Limited | Binding molecules against a piwil1 peptide-hla complex |
| WO2024146951A1 (en) | 2023-01-06 | 2024-07-11 | Immunocore Limited | Binding molecules against a prame peptide-hla complex |
| WO2025008513A1 (en) | 2023-07-05 | 2025-01-09 | Immatics Biotechnologies Gmbh | A method of identifying mhc-binding proteins and interacting peptides in a sample |
| AU2024300235A1 (en) | 2023-07-27 | 2026-01-08 | Immatics Biotechnologies Gmbh | Antigen binding proteins against mageb2 |
| WO2025085855A2 (en) * | 2023-10-20 | 2025-04-24 | BioNTech SE | Multispecific t cell engagers compositions and methods of use thereof |
| TW202530269A (zh) * | 2023-10-27 | 2025-08-01 | 大陸商北京可瑞生物科技有限公司 | 基於ｔ細胞受體的多特異性多肽分子及其組合物和用途 |
| CN122029198A (zh) * | 2023-11-01 | 2026-05-12 | 英美偌科有限公司 | 用于纯化小的多结构域蛋白质的方法 |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| GB202320012D0 (en) * | 2023-12-22 | 2024-02-07 | Immunocore Ltd | Bispecific molecules |
| WO2025233431A1 (en) | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof |
| GB2641580A (en) | 2024-06-07 | 2025-12-10 | T Therapeutics Ltd | Tumour-transforming multispecific proteins |
| WO2026025031A1 (en) | 2024-07-26 | 2026-01-29 | Modernatx, Inc. | Mrna encoding mageb2 tcer molecule |
| WO2026078231A1 (en) | 2024-10-11 | 2026-04-16 | T-Therapeutics Limited | Soluble non-aggregating immune ligand |
| WO2026096575A1 (en) | 2024-10-29 | 2026-05-07 | Modernatx, Inc. | Mrna encoding concatemeric prame epitope polypeptide |
| WO2026093563A2 (en) | 2024-10-31 | 2026-05-07 | Molecular Partners Ag | Multispecific binding proteins and their use |
| CN119529098B (zh) * | 2025-01-22 | 2025-05-30 | 北京可瑞生物科技有限公司 | 对mage-a1具有特异性的结合分子和抗cd3的融合蛋白 |
Family Cites Families (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2018248A1 (en) | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| PT744958E (pt) | 1994-01-31 | 2003-11-28 | Univ Boston | Bancos de anticorpos policlonais |
| DK0979281T3 (da) | 1997-05-02 | 2005-11-21 | Genentech Inc | Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| WO2002002781A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| WO2003029456A1 (en) | 2001-10-01 | 2003-04-10 | Dyax Corp. | Multi-chain eukaryotic display vectors and uses thereof |
| NZ539225A (en) | 2002-10-09 | 2006-09-29 | Avidex Ltd | Single chain recombinant T cell receptors |
| WO2006103429A2 (en) | 2005-04-01 | 2006-10-05 | Medigene Limited | High affinity hiv t cell receptors |
| ES2707152T3 (es) | 2005-04-15 | 2019-04-02 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
| US9284375B2 (en) * | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| ES2564823T3 (es) | 2005-05-27 | 2016-03-29 | Ospedale San Raffaele S.R.L. | Vector génico que comprende miARN |
| AT503861B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| WO2008045437A2 (en) | 2006-10-09 | 2008-04-17 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| EP2152751A1 (en) | 2007-05-31 | 2010-02-17 | Genmab A/S | Fusion or linked proteins with extended half life |
| US20100317546A1 (en) | 2008-01-11 | 2010-12-16 | Morphosys Ag | Display Vectors and Methods and Uses Thereof |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| US8465743B2 (en) | 2009-10-01 | 2013-06-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| EP2486049A1 (en) | 2009-10-06 | 2012-08-15 | The Board Of Trustees Of The UniversityOf Illinois | Human single-chain t cell receptors |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| SI2519543T1 (sl) | 2009-12-29 | 2016-08-31 | Emergent Product Development Seattle, Llc | Beljakovine, ki se vežejo s heterodimeri in njihova uporaba |
| WO2011085178A1 (en) | 2010-01-11 | 2011-07-14 | Trustees Of Dartmouth College | Monomeric bi-specific fusion protein |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| TWI638833B (zh) | 2010-11-30 | 2018-10-21 | 中外製藥股份有限公司 | 細胞傷害誘導治療劑 |
| KR101944557B1 (ko) | 2011-02-11 | 2019-01-30 | 메모리얼 슬로안 케터링 캔서 센터 | 에이치엘에이 제한된, 펩타이드특이성 항원 결합 단백질 |
| US20130078250A1 (en) * | 2011-08-23 | 2013-03-28 | Oliver Ast | Bispecific t cell activating antigen binding molecules |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| WO2014083004A1 (en) | 2012-11-30 | 2014-06-05 | Roche Glycart Ag | Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins |
| WO2014131711A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| WO2014131712A1 (en) * | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| CN111925437A (zh) * | 2013-03-14 | 2020-11-13 | 宏观基因有限公司 | 与表达激活受体的免疫效应细胞具有免疫反应性的双特异性分子 |
| EP4570318A3 (en) | 2013-11-27 | 2025-10-15 | Zymeworks BC Inc. | Bispecific antigen-binding constructs targeting her2 |
| MX379030B (es) | 2013-12-17 | 2025-03-10 | Genentech Inc | Anticuerpos anti-cd3 y metodos de uso |
| BR112016021918A2 (pt) | 2014-03-25 | 2017-10-24 | Merial Inc | composições imunológicas contendo histophilus somni atenuado |
| MX2017001079A (es) | 2014-07-24 | 2017-09-12 | Bluebird Bio Inc | Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma). |
| EP2985294A1 (en) | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Recombinant antibody molecule and its use for target cell restricted T cell activation |
| WO2016025880A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
| EP3221356B1 (en) * | 2014-11-20 | 2020-09-02 | F.Hoffmann-La Roche Ag | T cell activating bispecific antigen binding molecules against folr1 and cd3 |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| GB201423361D0 (en) | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| GB201504502D0 (en) | 2015-03-17 | 2015-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
| EP3270937A4 (en) | 2015-03-26 | 2018-09-12 | The Trustees Of Dartmouth College | Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| BR112017024757A2 (pt) | 2015-05-18 | 2018-11-13 | TCR2 Therapeutics Inc. | composições e métodos para reprogramação de tcr utilizando proteínas de fusão |
| EP3095792A1 (en) | 2015-05-19 | 2016-11-23 | Klinikum rechts der Isar der Technischen Universität München | T cell receptor with specificity for myeloperoxidase peptide and uses thereof |
| GB201510771D0 (en) | 2015-06-19 | 2015-08-05 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer |
| GB201511191D0 (en) | 2015-06-25 | 2015-08-12 | Immatics Biotechnologies Gmbh | T-cell epitopes for the immunotherapy of myeloma |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201511792D0 (en) | 2015-07-06 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers |
| GB201512369D0 (en) | 2015-07-15 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| US20170136108A1 (en) | 2015-08-28 | 2017-05-18 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201515321D0 (en) | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201517538D0 (en) | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| WO2017059900A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Cell & Gene Therapies Gmbh | Antigen receptors and uses thereof |
| JP6862435B2 (ja) | 2015-10-09 | 2021-04-21 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 抗ｗｔ１／ｈｌａ特異的抗体 |
| CN116059316A (zh) | 2015-10-23 | 2023-05-05 | 优瑞科生物技术公司 | 抗体/t细胞受体嵌合构建体及其用途 |
| GB201521746D0 (en) | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| GB201521894D0 (en) | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
| GB201522667D0 (en) | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| GB201522592D0 (en) * | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
| GB201602918D0 (en) | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| GB201603568D0 (en) | 2016-03-01 | 2016-04-13 | Immatics Biotechnologies Gmbh | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
| GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| CN109310764B (zh) | 2016-04-15 | 2022-01-14 | 达特茅斯大学理事会 | 高亲和力b7-h6抗体和抗体片段 |
| EP3472208B9 (en) | 2016-06-17 | 2023-10-04 | Medigene Immunotherapies GmbH | T cell receptors and uses thereof |
| CN109643503A (zh) | 2016-06-27 | 2019-04-16 | 宝洁公司 | 由口腔护理产品评估牙齿过敏处理的设备和方法 |
| WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| JP7012364B2 (ja) | 2016-08-05 | 2022-02-14 | 国立大学法人東北大学 | Ｔ細胞受容体の認識機構を用いたがん又は感染症の治療及び診断 |
| JP2020501508A (ja) | 2016-09-15 | 2020-01-23 | クアドルセプト バイオ リミテッド | 多量体、四量体および八量体 |
| CN106831996B (zh) | 2017-03-31 | 2020-05-19 | 北京智仁美博生物科技有限公司 | 具有cd3e和/或her2靶向功能的双特异性抗体及其用途 |
| CN111094333A (zh) | 2017-06-01 | 2020-05-01 | 斯图加特大学 | 异源二聚化的Ig结构域 |
| PT3428194T (pt) | 2017-07-14 | 2021-11-18 | Immatics Biotechnologies Gmbh | Molécula de polipéptido com especificidade dupla melhorada |
| US20200261502A1 (en) | 2017-09-08 | 2020-08-20 | Carsgen Therapeutics Co., Ltd. | Genetically engineered t cell and application thereof |
| EP3747456A4 (en) | 2018-01-31 | 2021-12-01 | Tohoku University | PROCESS FOR REGULATING THE EXPRESSION OF THE SPECIFIC MHC OF AN ANTIGEN |
| US20210363216A1 (en) | 2018-05-14 | 2021-11-25 | Immunocore Limited | Bifunctional binding polypeptides |
| EA202091977A1 (ru) | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| WO2020018715A1 (en) | 2018-07-17 | 2020-01-23 | Massachusetts Institute Of Technology | Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof |
| WO2020057610A1 (en) | 2018-09-20 | 2020-03-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific anti-ctla-4/pd-1 polypeptide complexes |
| GB201903767D0 (en) | 2019-03-19 | 2019-05-01 | Quadrucept Bio Ltd | Multimers, tetramers & octamers |
| GB201906685D0 (en) | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
| MX2022000667A (es) | 2019-07-15 | 2022-07-21 | Neogene Therapeutics B V | Metodo para aislar genes tcr. |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| US20210032370A1 (en) * | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| EP4025598A1 (en) | 2019-09-06 | 2022-07-13 | Eli Lilly and Company | Proteins comprising t-cell receptor constant domains |
| US20220396635A1 (en) | 2019-09-25 | 2022-12-15 | Universität Stuttgart | Trivalent binding molecules |
| BR112022004789A2 (pt) | 2019-09-27 | 2022-06-21 | Agenus Inc | Proteínas heterodiméricas |
| JP2023502625A (ja) | 2019-11-15 | 2023-01-25 | グリットストーン バイオ インコーポレイテッド | 共有新抗原を標的にする抗原結合タンパク質 |
| IL292996A (en) | 2019-11-18 | 2022-07-01 | Medigene Immunotherapies Gmbh | T cell receptors for prame and their uses |
| WO2021127184A1 (en) | 2019-12-17 | 2021-06-24 | The Johns Hopkins University | MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING |
| CN110964122B (zh) | 2019-12-24 | 2022-04-15 | 南京北恒生物科技有限公司 | T细胞受体融合蛋白及其用途 |
| US20230130925A1 (en) | 2020-03-16 | 2023-04-27 | University Of Southern California | Methods to prevent, ameliorate and treat complications from viral infections |
| EP4592310A2 (en) | 2020-03-16 | 2025-07-30 | Angeles Therapeutics, Inc. | Novel antigen binding domains and synthetic antigen receptors incorporating the same |
| WO2021222576A1 (en) | 2020-05-01 | 2021-11-04 | A2 Biotherapeutics, Inc. | Pag1 fusion proteins and methods of making and using same |
| AU2021289612A1 (en) | 2020-06-10 | 2023-01-19 | The University Of Melbourne | HIV-1 antibodies |
| JP2023536100A (ja) | 2020-07-27 | 2023-08-23 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ | 代替の翻訳開始および翻訳停止に由来する多機能免疫グロブリンフォールドポリペプチド |
| CA3195114A1 (en) | 2020-10-09 | 2022-04-14 | Martin Klatt | Compositions targeting ndc80/mhc complexes and uses thereof |
| WO2022083668A1 (en) | 2020-10-21 | 2022-04-28 | Nanjing Legend Biotech Co., Ltd. | Use of a chimeric co-stimulatory receptor for cell therapy |
| KR20230123474A (ko) | 2020-12-21 | 2023-08-23 | 자임워크스 비씨 인코포레이티드 | 안정화된 tcr 작제물 및 사용 방법 |
| KR20230153529A (ko) | 2021-02-19 | 2023-11-06 | 프리트 엠. 쇼드하리 | 다양한 면역세포를 위한 단일사슬 및 다중사슬 합성 항원 수용체 |
-
2018
- 2018-07-13 PT PT181835083T patent/PT3428194T/pt unknown
- 2018-07-13 MD MDE20200533T patent/MD3652215T2/ro not_active IP Right Cessation
- 2018-07-13 BR BR112020000762-5A patent/BR112020000762A2/pt unknown
- 2018-07-13 BR BR112020000769-2A patent/BR112020000769A2/pt not_active Application Discontinuation
- 2018-07-13 KR KR1020207004221A patent/KR20200026995A/ko not_active Ceased
- 2018-07-13 WO PCT/EP2018/069157 patent/WO2019012141A1/en not_active Ceased
- 2018-07-13 PL PL18740829T patent/PL3652215T3/pl unknown
- 2018-07-13 RS RS20210561A patent/RS61817B1/sr unknown
- 2018-07-13 KR KR1020207004219A patent/KR102833184B1/ko active Active
- 2018-07-13 EP EP21191794.3A patent/EP3985029A1/en active Pending
- 2018-07-13 CR CR20200014A patent/CR20200014A/es unknown
- 2018-07-13 CR CR20200013A patent/CR20200013A/es unknown
- 2018-07-13 CN CN201880046726.5A patent/CN110914308A/zh active Pending
- 2018-07-13 HR HRP20211744TT patent/HRP20211744T1/hr unknown
- 2018-07-13 PE PE2020000056A patent/PE20200614A1/es unknown
- 2018-07-13 MD MDE20190844T patent/MD3428194T2/ro not_active IP Right Cessation
- 2018-07-13 EP EP18740829.9A patent/EP3652215B1/en active Active
- 2018-07-13 US US16/035,403 patent/US11905328B2/en active Active
- 2018-07-13 SG SG11202000025SA patent/SG11202000025SA/en unknown
- 2018-07-13 AU AU2018298884A patent/AU2018298884A1/en not_active Abandoned
- 2018-07-13 SG SG11202000027WA patent/SG11202000027WA/en unknown
- 2018-07-13 CA CA3069842A patent/CA3069842A1/en active Pending
- 2018-07-13 LT LTEP18183508.3T patent/LT3428194T/lt unknown
- 2018-07-13 DK DK18740829.9T patent/DK3652215T3/da active
- 2018-07-13 JP JP2020501174A patent/JP2020530762A/ja active Pending
- 2018-07-13 LT LTEP18740829.9T patent/LT3652215T/lt unknown
- 2018-07-13 PE PE2020000058A patent/PE20200615A1/es unknown
- 2018-07-13 ES ES18183508T patent/ES2898210T3/es active Active
- 2018-07-13 CN CN201880046721.2A patent/CN110914307A/zh active Pending
- 2018-07-13 SI SI201830285T patent/SI3652215T1/sl unknown
- 2018-07-13 AU AU2018298881A patent/AU2018298881B2/en active Active
- 2018-07-13 EP EP18183508.3A patent/EP3428194B1/en active Active
- 2018-07-13 ES ES18740829T patent/ES2871146T3/es active Active
- 2018-07-13 US US16/035,420 patent/US20190016803A1/en not_active Abandoned
- 2018-07-13 WO PCT/EP2018/069151 patent/WO2019012138A1/en not_active Ceased
- 2018-07-13 MA MA46299A patent/MA46299B1/fr unknown
- 2018-07-13 SI SI201830456T patent/SI3428194T1/sl unknown
- 2018-07-13 PL PL18183508T patent/PL3428194T3/pl unknown
- 2018-07-13 CA CA3069610A patent/CA3069610A1/en active Pending
- 2018-07-13 DK DK18183508.3T patent/DK3428194T3/da active
- 2018-07-13 HU HUE18740829A patent/HUE054568T2/hu unknown
- 2018-07-13 PT PT187408299T patent/PT3652215T/pt unknown
- 2018-07-13 RS RS20211381A patent/RS62544B1/sr unknown
- 2018-07-13 US US16/035,412 patent/US20190016802A1/en not_active Abandoned
- 2018-07-13 HU HUE18183508A patent/HUE057110T2/hu unknown
- 2018-07-13 US US16/035,429 patent/US20190016804A1/en not_active Abandoned
- 2018-07-16 TW TW107124492A patent/TWI762677B/zh not_active IP Right Cessation
- 2018-07-16 TW TW110149543A patent/TWI817302B/zh not_active IP Right Cessation
- 2018-07-17 JP JP2018134424A patent/JP6784724B2/ja active Active
-
2020
- 2020-01-14 MX MX2020011744A patent/MX2020011744A/es unknown
- 2020-01-28 CO CONC2020/0001029A patent/CO2020001029A2/es unknown
- 2020-02-10 ZA ZA2020/00842A patent/ZA202000842B/en unknown
- 2020-02-11 CO CONC2020/0001491A patent/CO2020001491A2/es unknown
-
2021
- 2021-05-06 CY CY20211100387T patent/CY1124091T1/el unknown
- 2021-11-01 CY CY20211100934T patent/CY1124835T1/el unknown
-
2022
- 2022-03-03 US US17/686,358 patent/US20220185888A1/en not_active Abandoned
- 2022-03-12 US US17/693,323 patent/US20220195044A1/en not_active Abandoned
-
2023
- 2023-05-22 JP JP2023083663A patent/JP2023103451A/ja active Pending
- 2023-06-08 US US18/331,556 patent/US20230348598A1/en not_active Abandoned
- 2023-11-24 JP JP2023198791A patent/JP2024023385A/ja active Pending
-
2025
- 2025-06-17 US US19/240,392 patent/US20250361300A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3652215T3 (pl) | Ulepszona cząsteczka polipeptydu o podwójnej specyficzności | |
| IL285286A (en) | Transposase polypeptides and uses thereof | |
| IL283965A (en) | Antibodies against cd73 and uses thereof | |
| IL268862A (en) | Testing for particulates | |
| IL268920A (en) | Peptide vaccines | |
| EP3692489A4 (en) | QUANTUM ATTACK TEST CHAIN | |
| IL268593A (en) | Polypeptide variants and uses thereof | |
| FI3494134T3 (fi) | Muunneltuja polypeptidejä ja niiden käyttötapoja | |
| DK3723783T3 (da) | Mitokondrie-målrettede peptider | |
| EP3352760C0 (en) | CD3-BINDING POLYPEPTIDES | |
| IL248979B (en) | Syntac polypeptides and uses thereof | |
| EP3362556C0 (en) | POLYPEPTIDE VARIANTS | |
| DK4089113T3 (da) | Polypeptider | |
| IL254591A0 (en) | Polypeptides | |
| DK3723488T3 (da) | Terapeutiske bakteriociner | |
| EP3615471A4 (en) | PLASMA PHOTOELECTRONIC IMMUNE SENSOR | |
| PL3652405T3 (pl) | Materiał | |
| EP3684343A4 (en) | IMPROVED SUPRA ITEMS | |
| EP3634874A4 (en) | CLOSING | |
| DK3448879T3 (da) | Claudin-6 peptider | |
| EP3733686A4 (en) | NEW PEPTIDE | |
| EP3731387A4 (en) | Actuator | |
| EP3591265A4 (en) | BELLOWS | |
| EP3546672A4 (en) | CONSTRUCTION MATERIAL | |
| DK3423578T3 (da) | Polypeptidbibliotek |